Amgen appeals over orphan drug biosimilar ban
Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX
Copyright © Legal Benchmarking Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Amgen appeals over orphan drug biosimilar ban

Vials of liquid on a white table and the logo of a large pharmaceutical company.

Alexion obtained a preliminary injunction in Munich barring Amgen from selling a biosimilar version of its antibody drug

Amgen has appealed against a German court order issued last Friday, August 4, after having earlier been forced to pull a drug for a rare blood disorder from the German market.

Alexion, a UK-based biologics developer owned by AstraZeneca, asserted orphan drug exclusivity (ODE) rights on its antibody treatment Soliris (eculizumab) against Amgen at the Munich Regional Court earlier this year.

Soliris is approved by the European Medicines Agency (EMA) to treat paroxysmal nocturnal haemoglobinuria (PNH), a chronic blood condition, as well as other rare diseases.

The EMA approved Bekemv, Amgen’s biosimilar version of Soliris, for the treatment of PNH in April this year, after Alexion’s monopoly on that use of the drug expired.

But in May, days after Bekemv launched in Germany, Alexion obtained a preliminary injunction at the Munich court that restricted Amgen’s sale of the drug.

Alexion claimed there was a risk that Bekemv would be used for the off-label treatment of conditions other than PNH, for which Alexion still has exclusive rights.

Soliris is protected by ODE until later this year for atypical haemolytic uraemic syndrome, until 2027 for generalised myasthenia gravis, and until 2029 for neuromyelitis optica spectrum disorder.

The Munich court upheld May’s preliminary order last Friday, August 4, after finding that Amgen had contributed to the risk of off-label use of Bekemv by sending letters of recommendation to medical practitioners.

A spokesperson for Alexion said: "We are pleased with the court’s decision in that it helps protect some of the incentives that propel innovation in the rare disease space.”

Counsel for Amgen said the case was the first time the holder of ODE rights had asserted them against a competitor in Europe.

The court ruled Amgen couldn’t market Bekemv unless it met certain conditions, which its lawyers have described as “unreasonable” and “unbearable”.

Amgen, represented by Osborne Clarke and Bardehle Pagenberg, has appealed against the decision to the Federal Court of Justice.

According to Tilman Müller-Stoy, partner at Bardehle Pagenberg, the injunction is based entirely on the mere danger of off-label use.

The court’s order would require Amgen customers, including hospitals, to contractually agree not to make any off-label use of the drug, Müller-Stoy said.

Alexion has also sued Samsung’s biosimilars unit, Samsung Bioepis, at the same court. A hearing over a preliminary injunction in that case is scheduled for August 16.

The EMA approved Samsung Bioepis’s biosimilar version of eculizumab in May.

more from across site and ros bottom lb

More from across our site

We provide a rundown of Managing IP’s news and analysis from the week, and review what’s been happening elsewhere in IP
Tony Nguyen, who returned to Fish & Richardson this month after a year travelling overseas, tells Managing IP how and why he took the plunge
Tom Treutler, who previously managed the Vietnamese office of Tilleke & Gibbins, has joined East IP
Counsel discuss upcoming AI and data privacy legislation and what they’ve learned since Chile joined the Madrid Protocol
INTA has postponed its planned Annual Meeting in Dubai, but the organisation should think carefully about whether it wants to go there at all
The firm has named its new managing director after its former Asia head resigned earlier this year
As law firms explore how best to support clients at the UPC, members of the UPCLA network believe they have found the best of both worlds
The Industry Patent Quality Charter hosted a conference in which it discussed the importance of granting high-quality patents
Julia Holden explains why, if she weren’t in IP, she would be directing and producing live English-language theatre
The impact of the recently agreed treaty may be modest at first but is likely to become more significant over time
Gift this article